Avery Therapeutics is organized around advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle. ANchored in technology licensed fro University of Arizona, Tuscon, Averyâs first product, MyCardia⢠is a tissue engineered graft for treatment of chronic heart failure. Chronic heart failure is a critical need worldwide with 26M people diagnosed and no therapies that effectively reverse the disease process or restore function to the heart long term. MyCardia⢠has the potential to be the first available therapy that regenerates tissue and restores the heart to effective function for a high quality of life. MyCardia⢠is a three part product comprised of a bio- absorbable scaffold seeded with fibroblasts and induced pluripotent stem cell derived cardiomyocytes. Each cell type provides a unique therapeutic element and taken together synergistically improves the heart better than other technologies. MyCardia⢠mimics key molecular and cellular attributes of cardiac tissue and behaves like cardiac tissue. MyCardia⢠beats spontaneously and synchronously and electrically couples with the heart. The firm's data showing that MyCardia⢠improves cardiac function in pre-clinical models of heart failure and results in generation of new blood vessels and heart muscle. Pre-clinical studies with MyCardia⢠have also shown improvements in diastolic function. Given that there are no existing therapies to treat diastolic dysfunction these results could potentially beo
